Longeveron Inc. Class A Common Stock (LGVN)

FairStock Score: 27/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a value investor, I look for businesses that earn money, have durable competitive advantages, and can be bought at a discount to intrinsic worth. Longeveron does not fit that mold today. It is a 38-employee clinical-stage biotechnology company whose lead asset, LOMECEL-B, is in a Phase 3 trial for hypoplastic left heart syndrome and other earlier-stage programs. The commercial engine is barely running. In fiscal Q2 2026, the quarter ended June 30, 2026, revenue was $287,000 and net loss was $6.1 million. For fiscal year 2025, the year ended December 31, 2025, revenue was $1.2 million, down from $2.4 million in fiscal year 2024, the year ended December 31, 2024, while net loss widened to $22.7 million from $16.0 million. The Lynch classification is none because the company lost money in each of the last four years.

In plain English: Longeveron is a small clinical-stage biotechnology company testing cell therapies for serious heart and brain conditions. It has very little revenue and loses money; in fiscal Q2 2026, the quarter ended June 30, 2026, revenue was $287,000 and net loss was $6.1 million. At $2.15 a share as of 2026-10-13, the stock looks speculative and not supported by current profits, though it trades below its stated book value.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer